GlassScriptPhysician profile
Manuel Davila
NPI 1194709626
$33,498.26
in general payments reported to CMS, 2019-2025
42 companies · $5,550 in 2025
The $5,550 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,057 · 2020: $1,519 · 2021: $3,677 · 2022: $5,603 · 2023: $6,539 · 2024: $6,554 · 2025: $5,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18K · Education: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,329.16 |
| Education | $313.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,300.18 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $3,040.09 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $2,445.45 | 2019-2025 | |
| Incyte Corporation | $2,346.19 | 2021-2025 | Opzelura, Opzelura |
| Janssen Biotech, INC. | $2,101.51 | 2019-2025 | Tremfya |
| Leo Pharma INC. | $1,613.85 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Lilly USA, LLC | $1,522.99 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $1,398.67 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $1,395.88 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $1,368.05 | 2019-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,353.73 | 2019-2025 | Siliq, Jublia, Arazlo |
| Arcutis Biotherapeutics, INC. | $1,284.22 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $1,167.77 | 2019-2025 | |
| Genzyme Corporation | $1,094.03 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,079.28 | 2022-2025 | Sotyktu |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $952.52 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Hill Dermaceuticals, INC. | $832.91 | 2021-2024 | Tolak |
| Pfizer INC. | $632.58 | 2019-2025 | |
| Ucb, INC. | $547.49 | 2019-2025 | Bimzelx |
| Medimetriks Pharmaceuticals, INC. | $427.14 | 2019-2023 | |
| Epi Health, LLC | $379.65 | 2019-2022 | |
| Vyne Pharmaceuticals INC. | $342.67 | 2020-2021 | |
| Almirall LLC | $307.31 | 2020-2025 | Klisyri, Seysara |
| Mayne Pharma Commercial LLC | $265.59 | 2019-2025 | |
| Genentech USA, INC. | $210.88 | 2019-2024 | Erivedge |
| Celgene Corporation | $177.63 | 2019 | |
| Aclaris Therapeutics, INC. | $136.16 | 2019 | |
| Merz North America, INC. | $133.96 | 2025 | |
| Dermira, INC. | $118.90 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.94 | 2022-2023 | Spevigo |
| Paratek Pharmaceuticals, INC. | $69.83 | 2021-2024 | Nuzyra |
| Biofrontera INC. | $64.14 | 2019-2021 | |
| Organon LLC | $36.31 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $35.61 | 2024-2025 | Ycanth |
| Dusa Pharmaceuticals, INC. | $30.10 | 2019 | |
| Tempus Ai, INC | $26.59 | 2024 | Merlin Test |
| Sandoz INC. | $20.98 | 2020 | |
| Elekta, INC. | $16.71 | 2025 | Flexitron Hdr |
| Fidia Pharma USA INC. | $16.11 | 2025 | |
| Melinta Therapeutics, LLC | $11.57 | 2019 | |
| Allergan, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Davila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.